pepQ Family assigned · medium auto-curated

H37Rv Rv2535c · MTBC0 mtbc0_002701 · 372 aa · 2882190–2883308 MTBC0 (-) · RefSeq NP_217051.1

Genomic neighbourhood (genome browser)

Open in full genome browser →
+ strand − strand fas (Rv2524c) — requalified: fatty acid synthase fas Rv2525c (Rv2525c) — family_assigned: DUF1906 domain-containing protein vapB17 (Rv2526) — family_assigned: type II toxin-antitoxin system VapB family antitoxin vapC17 (Rv2527) — family_assigned: PIN domain-containing protein mrr (Rv2528c) — requalified: restriction endonuclease mrr vapC39 (Rv2530c) — family_assigned: type II toxin-antitoxin system VapC family toxin Rv2532c (Rv2532c) — requalified: antitermination protein NusB nusB (Rv2533c) — requalified: transcription antitermination factor NusB pepQ (Rv2535c) — family_assigned: Xaa-Pro peptidase family protein pepQ Rv2536 (Rv2536) — family_assigned: B-4DMT family transporter aroD (Rv2537c) — requalified: type II 3-dehydroquinate dehydratase aroB (Rv2538c) — requalified: 3-dehydroquinate synthase aroB aroK (Rv2539c) — requalified: shikimate kinase AroK aroF (Rv2540c) — requalified: chorismate synthase aroF Rv2542 (Rv2542) — family_assigned: alpha/beta hydrolase family protein Rv2542 lppA (Rv2543) — family_assigned: LppA family lipoprotein lppB (Rv2544) — family_assigned: LppA family lipoprotein vapB18 (Rv2545) — family_assigned: type II toxin-antitoxin system VapB family antitoxin vapC18 (Rv2546) — family_assigned: PIN domain nuclease vapB19 (Rv2547) — family_assigned: CopG family transcriptional regulator vapC19 (Rv2548) — family_assigned: type II toxin-antitoxin system VapC family toxin vapC20 (Rv2549c) — requalified: type II toxin-antitoxin system toxin 23S rRNA-specific endon vapB20 (Rv2550c) — requalified: type II toxin-antitoxin system antitoxin VapB20 Rv2551c (Rv2551c) — family_assigned: A24 family peptidase 2 872 kb 2 876 kb 2 880 kb 2 884 kb 2 888 kb 2 892 kb

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)cytoplasmic peptidase PepQ
MTBC0 PGAP re-annotationXaa-Pro peptidase family protein
Revised (this work)Xaa-Pro peptidase family protein. Pfam: Creatinase_N (PF01321.25), Peptidase_M24 (PF00557.30).
Functional category (TubercuList)intermediary metabolism and respiration

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 45 publications

45 TB publications mention this gene. 45 publications discuss this gene. Queried separately, 45 records carry a M. tuberculosis context and 1 a non-TB mycobacterial context (species named in the 1-record verified sample: M. smegmatis (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 45: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Bedaquiline resistance: a predictable consequence of a game-changing drug? doi:10.1128/asmcr.00228-25 2026
Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China. doi:10.1128/spectrum.02664-25 2026
Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis. doi:10.1016/j.ijmmb.2026.101163 2026
Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review. doi:10.1186/s12879-026-13171-3 2026
Bedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends. doi:10.3390/antibiotics15040385 2026
47 records returned by the alias sweep (a separate sweep from the 45 above; both are shown, neither is exhaustive)

Searched as: Rv2535c, pepQ, Mb2564c, ML0521, MMAR_2180, MSMEG_3034, MAB_2838c — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
No phenotypic resistance observed for most group-3 and -4 variants in Mycobacterium tuberculosis genes related to bedaquiline, clofazimine, delamanid, and pretomanid in a Central and West African context. doi:10.1128/spectrum.02005-26 Microbiol Spectr 2026
Bedaquiline resistance: a predictable consequence of a game-changing drug? doi:10.1128/asmcr.00228-25 ASM Case Rep 2026
Comparative in vitro antimicrobial susceptibility profiles of clofazimine and pyrifazimine against clinical isolates of Mycobacterium tuberculosis in southwest China. doi:10.1128/spectrum.02664-25 Microbiol Spectr 2026
Phenotypic drug susceptibility testing and genotypic characterization of Bedaquiline resistance in drug resistant Mycobacteriumtuberculosis. doi:10.1016/j.ijmmb.2026.101163 Indian J Med Microbiol 2026
Global mapping of bedaquiline-resistant Mycobacterium tuberculosis: a systematic review. doi:10.1186/s12879-026-13171-3 BMC Infect Dis 2026
Bedaquiline Resistance in Drug-Resistant Tuberculosis in South Africa: A Systematic Review and Meta-Analysis of Emerging Trends. doi:10.3390/antibiotics15040385 Antibiotics (Basel) 2026
Acquisition of bedaquiline and clofazimine resistance in association with a novel loss-of-function mutation in the pepQ gene during treatment of multidrug-resistant tuberculosis. doi:10.1128/asmcr.00126-25 names it ASM Case Rep 2026
Bedaquiline Resistance: A Looming Global Threat in Tuberculosis Management. doi:10.1007/s00284-025-04655-7 Curr Microbiol 2025
Examination of Genetic Mutations of Clofazimine Resistance in Drug-Resistant Mycobacterium TB Isolates. doi:10.1007/s00284-025-04582-7 Curr Microbiol 2025
Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran. doi:10.1186/s12866-025-04213-y BMC Microbiol 2025
Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia. doi:10.1371/journal.pone.0326794 PLoS One 2025
An improved catalogue for whole-genome sequencing prediction of bedaquiline resistance in Mycobacterium tuberculosis using a reproducible algorithmic approach. doi:10.1099/mgen.0.001429 Microb Genom 2025
[Bedaquiline susceptibility and molecular mutation characteristics of Mycobacterium tuberculosis in Guizhou Province]. doi:10.3760/cma.j.cn112147-20250123-00050 Zhonghua Jie He He Hu Xi Za Zhi 2025
In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis. doi:10.1093/jac/dkae405 J Antimicrob Chemother 2025
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis. doi:10.1002/jcla.25091 J Clin Lab Anal 2024
Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China. doi:10.1371/journal.pone.0311042 PLoS One 2024
Mutations in Rv0678, Rv2535c, and Rv1979c Confer Resistance to Bedaquiline in Clinical Isolates of Mycobacterium Tuberculosis. doi:10.2174/0118761429314641240815080447 names it Curr Mol Pharmacol 2024
Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: A cross-sectional analysis. doi:10.1016/j.nmni.2024.101437 New Microbes New Infect 2024
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis. doi:10.1016/S2666-5247(23)00317-8 Lancet Microbe 2024
Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis. doi:10.1093/cid/ciad596 Clin Infect Dis 2024
In silico structural and mechanical insights into bedaquiline resistance associated with high-grade non-synonymous mutations in atpE, mmpR5, and pepQ. doi:10.1080/07391102.2023.2259486 names it J Biomol Struct Dyn 2024
Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis. doi:10.3389/fmed.2023.1304857 Front Med (Lausanne) 2023
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study. doi:10.1016/S2666-5247(23)00172-6 Lancet Microbe 2023
Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China. doi:10.2147/IDR.S429003 Infect Drug Resist 2023
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678. doi:10.1038/s41598-023-36955-y Sci Rep 2023
A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant. doi:10.1371/journal.pone.0287019 PLoS One 2023
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: an individual isolate metaanalysis. doi:10.1101/2023.05.04.23289023 medRxiv 2023
Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis. doi:10.1016/j.jgar.2023.05.001 J Glob Antimicrob Resist 2023
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. doi:10.1016/j.jgar.2023.04.003 J Glob Antimicrob Resist 2023
Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis. doi:10.3389/fcimb.2022.807095 Front Cell Infect Microbiol 2022
Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis. doi:10.1007/s00284-022-02881-x Curr Microbiol 2022
Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates. doi:10.3390/jcm11071927 J Clin Med 2022
Variants associated with Bedaquiline (BDQ) resistance identified in Rv0678 and efflux pump genes in Mycobacterium tuberculosis isolates from BDQ naïve TB patients in Pakistan. doi:10.1186/s12866-022-02475-4 BMC Microbiol 2022
Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. doi:10.1016/s2666-5247(21)00175-0 Lancet Microbe 2021
Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan. doi:10.3389/fmicb.2021.754249 Front Microbiol 2021
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. doi:10.1038/s41598-021-98862-4 Sci Rep 2021
Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis. doi:10.1016/j.ijid.2020.10.081 Int J Infect Dis 2021
Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. doi:10.1016/S2666-5247(20)30031-8 Lancet Microbe 2020
Molecular characteristics and in vitro susceptibility to bedaquiline of Mycobacterium tuberculosis isolates circulating in Shaanxi, China. doi:10.1016/j.ijid.2020.07.044 Int J Infect Dis 2020
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. doi:10.1093/jac/dkaa136 J Antimicrob Chemother 2020
Whole Genome Sequencing for the Analysis of Drug Resistant Strains of Mycobacterium tuberculosis: A Systematic Review for Bedaquiline and Delamanid. doi:10.3390/antibiotics9030133 Antibiotics (Basel) 2020
Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. doi:10.1016/j.dib.2018.09.057 Data Brief 2018
In vitro approaches for generation of Mycobacterium tuberculosis mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants. doi:10.1016/j.mimet.2018.08.011 J Microbiol Methods 2018
Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. doi:10.1093/cid/cix992 Clin Infect Dis 2018
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. doi:10.1093/jac/dkx094 J Antimicrob Chemother 2017
Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. doi:10.1128/AAC.00753-16 names it Antimicrob Agents Chemother 2016
Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. doi:10.1093/jac/dkv150 J Antimicrob Chemother 2015

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

CRISPRi vulnerability

Vulnerability index -2.48 (95% CI -8.01 to 3.50). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Caveat on this estimate. Bosch et al. flag this gene's vulnerability estimate as NOT certain, and here that call has a mechanical cause visible in the library itself: every guide targeting this gene is >=21 nt (str_span=0.269 on a 0-1 scale, near the genome floor), and guide repression strength saturates from 21 nt on -- so the library never sampled a partial knockdown for this gene, only the near-maximal repression plateau. The dose-response fit (and this VI) is therefore essentially unconstrained by data, not merely uncertain -- a limitation of the CRISPRi library design for the non-essential class (Bosch et al. 2021), not a defect in this specific measurement. n_guides=7 is descriptive only and does not predict this. Do not cite this VI as a standalone vulnerability claim.

Legacy record & comparison (Mycobrowser)

Mycobrowser functionFunction unknown; hydrolyses peptides.
Mycobrowser EC 3.4.13.9 · agrees with the atlas

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb2564c · 99.7% identity
M. leprae ML0521 · 82.7% identity
M. marinum MMAR_2180 · 83.9% identity
M. smegmatis MSMEG_3034 · 72.0% identity
M. orygis RJtmp_002624 · 99.7% identity
M. abscessus MAB_2838c · 64.7% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt I6YDN6 TrEMBL · unreviewed · Evidence at protein level
UniProt nameProbable cytoplasmic peptidase PepQ

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category E Amino acid transport and metabolism
Preferred namepepQ
eggNOG descriptionCreatinase/Prolidase N-terminal domain
Orthologous groupCOG0006
EC number EC 3.4.11.9, EC 3.4.13.9
KEGG orthology K01262, K01271
Gene Ontology (35) GO:0003674, GO:0003824, GO:0004177, GO:0005488, GO:0005515, GO:0005575, GO:0005622, GO:0005623, GO:0005737, GO:0005829, GO:0006508, GO:0006807 +23 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS n/a
Polymorphic sites (≥ 0.1% of strains) 0 synonymous, 3 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

M. canettii dN/dS (deep-divergence selection) undefined (dS = 0) (low power) · 1 consensus substitution(s)
low power (1 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 82.5% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 10/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 52.0%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis)

DeJesus 2017 callNE · non-essential
What the call meansnon-essential
TA sites (Himar1) 20 in the ORF — 0 in the essential state, 0 growth-defect, 20 non-essential, 0 growth-advantage. Saturation 0.950, mean read count 51.6842105263. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 20 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Mutant phenotypes (conditional Tn-seq, MtbTnDB) in-vivo phenotype

Conditionlog2FCqEffect
fitness after prolonged in vitro passage (in vitro passage) -6.220.0 required
fitness in mouse infection, day 45 (in vivo) -5.340.0 required
differential fitness in a comparison whose nature could not be established (upstream metadata defect, see note) (undetermined) +5.040.0 disruption advantageous
altered fitness under 6 weeks hypoxia (stress) -3.260.0 required
altered fitness under Isoniazid (drug exposure) -3.230.0 required
fitness in mouse infection (in vivo) +2.940.0 disruption advantageous
altered fitness under Isoniazid (drug exposure) -2.620.0 required
altered fitness under Meropenem (drug exposure) -2.600.041 required
fitness in mouse infection (in vivo) +2.570.011 disruption advantageous
altered fitness under 3 weeks hypoxia (stress) -1.940.013 required

Conditional fitness of transposon-disruption mutants across 10 significant condition(s) (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Provenance note on a condition above. MtbTnDB labels this condition in vivo (Collaborative Cross mouse panel) and attributes it to Smith et al. 2022, eLife 74419. Both are wrong and for the same reason: its left arm, `mbio_H37Rv`, is the saturated H37Rv reference of DeJesus et al. 2017 (mBio 8(1):e02133-16, fourteen independent Tn libraries grown in standard medium), not a mouse strain, and the upstream generator read the token before `_vs_` as a mouse-strain name. The same sample is the in vitro control of six knockout screens in the same file. Measured here on rank correlation over 3971 genes: this condition tracks the other 81 first-order in vivo conditions at rho = +0.03, where those conditions track each other at +0.270 -- it does not behave like an infection measurement. What the comparison actually is could not be established, so it is reported as undetermined rather than renamed, and it is excluded from the in vivo count of this fiche.

Drug resistance (WHO catalogue) bedaquilineclofazimine

bedaquiline124 catalogued resistance-associated variant(s)
clofazimine120 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 14 of 16 independent MS datasets
Integrated abundance419.0 ppm · rank 481/3519 (86.4th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length372 aa
Molecular weight38.8 kDa
Theoretical pI5.26
GRAVY0.055 (hydrophobic)
Aliphatic index100.8
Aromaticity0.046
Instability index20.2 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
Creatinase_NPF01321.25 4.3e-266–134 Creatinase/Prolidase N-terminal domain
Peptidase_M24PF00557.30 2.9e-67142–344 Metallopeptidase family M24

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 5e2c (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 1 solved

PDBMethodResolutionCoverage
5e2c X-ray diffraction 1.7 Å 35%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (1 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 96.4

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
3q6d-assembly2_B 1.00 0.96 0.92 0.96 39% 100% / 100% 1.1e-43 sig 3q6d-assembly2_B Xaa-Pro dipeptidase from Bacillus anthracis.
5giu-assembly1_A-2 1.00 0.93 0.87 0.93 39% 98% / 99% 6.6e-39 sig 5giu-assembly1_A-2 Crystal structure of Xaa-Pro peptidase from Deinococcus radiodurans, metal-free active site
2zsg-assembly1_A 1.00 0.91 0.88 0.91 33% 98% / 99% 2.3e-38 sig 2zsg-assembly1_A Crystal structure of X-Pro aminopeptidase from Thermotoga maritima MSB8
2zsg-assembly1_B 1.00 0.90 0.86 0.90 33% 95% / 98% 1.1e-38 sig 2zsg-assembly1_B Crystal structure of X-Pro aminopeptidase from Thermotoga maritima MSB8
5cnx-assembly1_C 1.00 0.92 0.89 0.92 33% 99% / 99% 1.6e-38 sig 5cnx-assembly1_C Crystal structure of Xaa-Pro aminopeptidase from Escherichia coli K12

Foldseek search of the AlphaFold DB model (mean pLDDT 96.4, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 4

Upstream (5' on genome)efp (- strand, 9 bp gap)
Downstream (3' on genome)Rv2536 (+ strand, 33 bp gap)
Predicted operon Rv2532c · nusB · efp · pepQ

Neighbours from the H37Rv annotation (- strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 3: nusB · efp · pepQ — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT2610) exponential phase: operon of 6, Rv2530A · Rv2530c · Rv2531c · Rv2533c · Rv2534c · Rv2535c (coverage 97.88)
stationary phase: operon of 2, Rv2534c · Rv2535c (coverage 27.44) — disagrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (2 TF) Rv1990c (represses) · Rv2250c (represses)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: efp (elongation factor P), high confidence (score 928, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence).

Showing the 15 strongest of this gene's 70 partners at medium confidence (12 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 70 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv2534c efp elongation factor P 951 928 ctx neighborhood:882
Rv2532c hypothetical protein 889 889 ctx neighborhood:882
Rv2533c nusB N utilization substance protein B 911 888 ctx neighborhood:882
Rv2536 transmembrane protein 795 796 ctx neighborhood:790
Rv2531c amino acid decarboxylase 700 628 ctx neighborhood:596
Rv2438c nadE curated glutamine-dependent NAD(+) synthetase 620 620 database:497
Rv2537c aroD 3-dehydroquinate dehydratase 596 596 ctx fusion:513
Rv0480c curated amidohydrolase 558 558 database:497
Rv2996c serA1 D-3-phosphoglycerate dehydrogenase 535 536
Rv2530A vapB39 antitoxin VapB39 517 518 ctx neighborhood:515
Rv2530c vapC39 ribonuclease VapC39 599 517 ctx neighborhood:514
Rv3336c trpS tryptophan--tRNA ligase 522 502
Rv0194 multidrug ABC transporter ATPase/permease 504 486
Rv2218 lipA curated lipoyl synthase 447 448 database:424
Rv0728c serA2 D-3-phosphoglycerate dehydrogenase SerA 441 441

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: cytoplasmic peptidase PepQ
  • MTBC0 PGAP product: Xaa-Pro peptidase family protein
  • Pfam (hmmscan --cut_ga): Creatinase_N PF01321.25 (E=4e-26), Peptidase_M24 PF00557.30 (E=3e-67)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_217051.1)
  • Domains: Pfam-A via hmmscan --cut_ga — Creatinase_N (PF01321.25), Peptidase_M24 (PF00557.30)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG0006
  • Curated reference: UniProt I6YDN6 (TrEMBL, unreviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 96.4)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 70 functional partner(s); context anchor efp
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_002701|Rv2535c|pepQ
MTHSQRRDKLKAQIAASGLDAMLISDLINVRYLSGFSGSNGALLVFADERDAVLATDGRYRTQAASQAPDLEVAIERAVGRYLAGRAGEAGVGKLGFESHVVTVDGLDALAGALEGKNTELVRASGTVESLREVKDAGELALLRLACEAADAALTDLVARGGLRPGRTERQVSRELEALMLDHGADAVSFETIVAAGANSAIPHHRPTDAVLQVGDFVKIDFGALVAGYHSDMTRTFVLGKAADWQLEIYQLVAEAQQAGRQALLPGAELRGVDAAARQLIADAGYGEHFGHGLGHGVGLQIHEAPGIGVTSAGTLLAGSVVTVEPGVYLPGRGGVRIEDTLVVAGGTPKMPETAGQTPELLTRFPKELAIL